SCHEMBL13499017

SCHEMBL13499017

Cc1cc(C(=O)Nc2cccc(Oc3ccc4nc(NC(=O)c5cccc(C(F)(F)F)c5)cn4n3)c2)n(C)n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.76
PDGFRB P09619 3/20 0.71
FLT1 P17948 3/20 0.71
KIT P10721 2/20 0.71
AURKA O14965 1/20 0.71
BRAF P15056 3/20 0.68
PDGFRA P16234 2/20 0.61
FGFR1 P11362 1/20 0.61
FGFR3 P22607 1/20 0.61
TEK Q02763 1/20 0.61
MET P08581 1/20 0.58
ABL1 P00519 1/20 0.54
CSF1R P07333 1/20 0.54
YES1 P07947 1/20 0.54
RET P07949 1/20 0.54
BCR P11274 1/20 0.54
FLT4 P35916 1/20 0.54
ABL2 P42684 1/20 0.54
DDR1 Q08345 1/20 0.54
DDR2 Q16832 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13499028 0.94 KDR (0.74) KDRPDGFRBFLT1KITAURKA
SCHEMBL3486662 0.90 KDR (0.85) KDRPDGFRBFLT1KITAURKA
SCHEMBL3486263 0.88 KDR (0.84) KDRPDGFRBFLT1KITAURKA
SCHEMBL2514277 0.88 KDR (0.83) KDRPDGFRBFLT1KITAURKA
SCHEMBL13499015 0.87 KDR (1.00) KDRPDGFRBFLT1KITAURKA
SCHEMBL12206497 0.87 KDR (0.82) KDRPDGFRBFLT1KITAURKA
SCHEMBL13499009 0.86 KDR (0.81) KDRPDGFRBFLT1KITAURKA
SCHEMBL2516131 0.86 KDR (0.81) KDRPDGFRBFLT1KITAURKA
SCHEMBL13499014 0.86 KDR (0.83) KDRPDGFRBFLT1KITAURKA
SCHEMBL2516587 0.86 KDR (0.81) KDRPDGFRBFLT1KITAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND IRAK1, IL1R1, IRAK2 KDR 1805/4885PDGFRB 1828/4885FLT1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.